Nearsightedness
0
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Bausch HealthQUEBEC, Quebec, Canada
1 programExperimental: Myopic defocus soft lens designN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
SydnexisSYD-101 0.01%
Bausch HealthExperimental: Myopic defocus soft lens design
Clinical Trials (2)
Total enrollment: 877 patients across 2 trials
The Safety and Efficacy of SYD-101 in Children With Myopia
Start: Apr 2019Est. completion: May 2025852 patients
Phase 3Completed
Effect of Defocus in Soft Contact Lenses on Internal Retinal Vascularization
Start: Jun 2024Est. completion: Mar 202525 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.